Tedatioxetine

DB12641InvestigationalSmall molecule

Tedatioxetine has been used in trials studying the treatment of Major Depressive Disorder.

Mechanism: Pharmacologically active on 5-hydroxytryptamine receptor 2A, Sodium-dependent noradrenaline transporter, and Alpha-1A adrenergic receptor
Curator reviewed
Formula / weight: C₁₈H₂₁NS · 283.43 g/mol (avg)
Code names: LU AA24530

Resolves to

Compound

Structure

InChIKeyCVASBKDYSQKLSO-UHFFFAOYSA-NSMILESCC1=CC=C(SC2=CC=CC=C2C2CCNCC2)C=C1

Targets

What you can answer from here — as of June 15, 2026

6Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

17+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tedatioxetine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.